EA201170983A1 - Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии - Google Patents

Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии

Info

Publication number
EA201170983A1
EA201170983A1 EA201170983A EA201170983A EA201170983A1 EA 201170983 A1 EA201170983 A1 EA 201170983A1 EA 201170983 A EA201170983 A EA 201170983A EA 201170983 A EA201170983 A EA 201170983A EA 201170983 A1 EA201170983 A1 EA 201170983A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapy
tiadiazoles
oxadiazoles
derivatives
receiving
Prior art date
Application number
EA201170983A
Other languages
English (en)
Inventor
Эйкмар Фетт
Патрик Мужено
Клоди Наман
Эрик Николе
Кристоф Филиппо
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42261833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170983(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0900359A external-priority patent/FR2941457A1/fr
Priority claimed from FR0904137A external-priority patent/FR2949464B1/fr
Application filed by Санофи filed Critical Санофи
Publication of EA201170983A1 publication Critical patent/EA201170983A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к соединениям, отвечающим формуле (I), в состоянии (i) основания или соли присоединения кислоты или в состоянии (ii) кислоты или соли присоединения основания, а также к способу их получения и к их применению в терапии.
EA201170983A 2009-01-28 2010-01-27 Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии EA201170983A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0900359A FR2941457A1 (fr) 2009-01-28 2009-01-28 Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique
FR0904137A FR2949464B1 (fr) 2009-09-01 2009-09-01 Derives de thiadiazoles et d'oxadiazoles, leur preparation et leur application en therapeutique
PCT/FR2010/050124 WO2010086551A1 (fr) 2009-01-28 2010-01-27 Dérivés de thiadiazoles et d'oxadiazoles, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
EA201170983A1 true EA201170983A1 (ru) 2012-03-30

Family

ID=42261833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170983A EA201170983A1 (ru) 2009-01-28 2010-01-27 Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии

Country Status (26)

Country Link
US (1) US8546391B2 (ru)
EP (1) EP2391611B1 (ru)
JP (1) JP2012516312A (ru)
KR (1) KR20110112845A (ru)
CN (1) CN102365273A (ru)
AR (1) AR075177A1 (ru)
AU (1) AU2010209545A1 (ru)
BR (1) BRPI1007414A2 (ru)
CA (1) CA2750742A1 (ru)
CL (1) CL2011001839A1 (ru)
CO (1) CO6400221A2 (ru)
CR (1) CR20110403A (ru)
DO (1) DOP2011000245A (ru)
EA (1) EA201170983A1 (ru)
EC (1) ECSP11011224A (ru)
IL (1) IL214260A0 (ru)
MA (1) MA33069B1 (ru)
MX (1) MX2011007991A (ru)
NI (1) NI201100149A (ru)
NZ (1) NZ594244A (ru)
PE (1) PE20120362A1 (ru)
TN (1) TN2011000353A1 (ru)
TW (1) TW201031645A (ru)
UY (1) UY32405A (ru)
WO (1) WO2010086551A1 (ru)
ZA (1) ZA201105525B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
CN102557941B (zh) * 2010-12-07 2015-04-22 成都睿智化学研究有限公司 一种螺环丙基甲酰衍生物的中间体化合物的制备方法
WO2014054053A1 (en) * 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014060381A1 (de) * 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CA2931313C (en) * 2013-11-21 2022-04-05 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
WO2015106272A1 (en) * 2014-01-13 2015-07-16 Harki Daniel A Small molecule inhibitors of apobec3g and apobec3b
EP3034500A1 (en) * 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
EP3259256B1 (en) * 2015-02-17 2022-03-09 Beijing Erai Therapeutics Co., Ltd. Compounds and methods for inducing browning of white adipose tissue
CN106278895B (zh) * 2015-05-15 2021-07-09 Dic株式会社 羧酸化合物、其制造方法、使用该化合物的液晶组合物
WO2019193540A1 (en) * 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2023060573A1 (en) * 2021-10-15 2023-04-20 Beijing Danatlas Pharmaceutical Co., Ltd. Novel thiadiazolyl derivatives of dna polymerase theta inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20050143384A1 (en) * 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
CA2549385A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
GB0427328D0 (en) * 2004-12-14 2005-01-19 Astrazeneca Ab Chemical compounds
EP1893592A1 (en) 2005-06-11 2008-03-05 AstraZeneca AB Oxadiazole derivatives as dgat inhibitors
GB0511851D0 (en) * 2005-06-11 2005-07-20 Astrazeneca Ab Chemical compounds
CA2648074A1 (en) * 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds

Also Published As

Publication number Publication date
CA2750742A1 (fr) 2010-08-05
US20120040984A1 (en) 2012-02-16
TN2011000353A1 (fr) 2013-03-27
TW201031645A (en) 2010-09-01
BRPI1007414A2 (pt) 2018-03-06
ECSP11011224A (es) 2011-08-31
US8546391B2 (en) 2013-10-01
JP2012516312A (ja) 2012-07-19
DOP2011000245A (es) 2011-09-15
NI201100149A (es) 2011-11-01
CO6400221A2 (es) 2012-03-15
AU2010209545A1 (en) 2011-08-18
CL2011001839A1 (es) 2012-01-06
PE20120362A1 (es) 2012-05-04
KR20110112845A (ko) 2011-10-13
MX2011007991A (es) 2011-11-18
IL214260A0 (en) 2011-09-27
MA33069B1 (fr) 2012-02-01
EP2391611A1 (fr) 2011-12-07
UY32405A (es) 2010-08-31
EP2391611B1 (fr) 2014-04-30
NZ594244A (en) 2013-07-26
ZA201105525B (en) 2012-12-27
CN102365273A (zh) 2012-02-29
AR075177A1 (es) 2011-03-16
CR20110403A (es) 2011-09-21
WO2010086551A1 (fr) 2010-08-05

Similar Documents

Publication Publication Date Title
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
EA201291436A1 (ru) Производные гексафторизопропил карбамата, их получение и их терапевтическое применение
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201270339A1 (ru) Замещенные производные ксантина
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA201100969A1 (ru) Солевые формы органического соединения
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
EA201170922A1 (ru) Производные сульфонамида
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201290632A1 (ru) Производные бетулина
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии